Knight Therapeutics Inc. Annual General Meeting Voting Results

MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) pharmaceutical company, announced today the voting results from the Annual General Meeting of the Shareholders held virtually in Montreal, Quebec ("Meeting").

Knight Therapeutics Inc. held its Annual General Meeting (AGM) on May 6, 2026, where significant outcomes regarding corporate governance and strategic direction were disclosed. The meeting is a cornerstone for shareholders to engage with management and express their views on the company’s future.

During the AGM, the voting results showcased overwhelming support for the re-election of the board of directors, including key figures in the pharmaceutical and biopharmaceutical sectors. This re-election is crucial as it emphasizes the shareholders' confidence in the management team and their strategic vision for the company's growth.

Also addressed were the financial performance metrics of Knight Therapeutics, which highlighted substantial advancements in research and development. Shareholders were informed about ongoing and upcoming pharmaceutical launches, which are pivotal to the company’s market positioning and competitive strategy.

Furthermore, the meeting covered significant resolutions to appoint external auditors and approve the remuneration plan for executives. These resolutions were passed with considerable majorities, signifying shareholders’ alignment with the company's planned operational framework and compensation strategy.

Additionally, the engagement with shareholders was notably interactive, as numerous questions were raised regarding the company's strategic initiatives and long-term objectives. The management’s proactive and transparent responses reinforced their commitment to stakeholder engagement and corporate accountability.

In conclusion, the AGM not only reaffirmed the trust in Knight Therapeutics' leadership but also set a robust foundation for the company’s future growth trajectory. The resolutions passed, along with the multiplex discussions, signal a healthy and engaged shareholder community, which is vital for the sustained success of Knight Therapeutics Inc.